WPD PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.005 CAD | -50.00% |
|
-50.00% | -88.89% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 69.14 | 33.46 | 4.538 | 5.105 | 5.105 |
| Enterprise Value (EV) 1 | 66.45 | 32.34 | 5.28 | 5.081 | 5.323 |
| P/E ratio | -0.18 x | -4.44 x | -0.81 x | 1.32 x | -63.8 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | -19.6 x | -4.03 x | -0.91 x | -2.25 x | -22.8 x |
| EV / FCF | -381,337,739 x | -41,381,192 x | -6,048,361 x | -1,162,496 x | -52,864,392 x |
| FCF Yield | -0% | -0% | -0% | -0% | -0% |
| Price to Book | 21.6 x | 30.2 x | -1.12 x | -10.7 x | -9.18 x |
| Nbr of stocks (in thousands) | 111,520 | 113,438 | 113,438 | 113,438 | 113,438 |
| Reference price 2 | 0.6200 | 0.2950 | 0.0400 | 0.0450 | 0.0450 |
| Announcement Date | 7/30/20 | 6/3/21 | 1/26/24 | 1/26/24 | 5/7/24 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -0.8907 | -3.389 | -8.029 | -5.816 | -2.254 | -0.2332 |
| EBIT 1 | -0.9003 | -3.429 | -8.36 | -6.099 | -2.272 | -0.2336 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.9271 | -11.61 | -7.523 | -5.623 | 3.857 | -0.0801 |
| Net income 1 | -0.9271 | -11.61 | -7.523 | -5.623 | 3.857 | -0.0801 |
| Net margin | - | - | - | - | - | - |
| EPS | - | -3.399 | -0.0665 | -0.0496 | 0.0340 | -0.000705 |
| Free Cash Flow | - | -0.1742 | -0.7815 | -0.873 | -4.371 | -0.1007 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 7/30/20 | 7/30/20 | 6/3/21 | 1/26/24 | 1/26/24 | 5/7/24 |
1CAD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 0.52 | - | - | 0.74 | - | 0.22 |
| Net Cash position 1 | - | 2.7 | 1.12 | - | 0.02 | - |
| Leverage (Debt/EBITDA) | -0.58 x | - | - | -0.1277 x | - | -0.9349 x |
| Free Cash Flow | - | -0.17 | -0.78 | -0.87 | -4.37 | -0.1 |
| ROE (net income / shareholders' equity) | - | -904% | -349% | 381% | -170% | 15.5% |
| ROA (Net income/ Total Assets) | - | -98.6% | -155% | -168% | -146% | -69.1% |
| Assets 1 | - | 11.78 | 4.865 | 3.354 | -2.634 | 0.1158 |
| Book Value Per Share | - | 0.0300 | 0.0100 | -0.0400 | -0 | -0 |
| Cash Flow per Share | - | 0.0300 | 0.0100 | 0 | 0 | 0 |
| Capex 1 | 0.04 | - | 0.06 | 0 | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 7/30/20 | 7/30/20 | 6/3/21 | 1/26/24 | 1/26/24 | 5/7/24 |
1CAD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -88.89% | 422K | |
| +20.12% | 126B | |
| +25.25% | 119B | |
| +25.56% | 27.95B | |
| -19.51% | 20.5B | |
| -14.36% | 17.12B | |
| -15.63% | 16.1B | |
| -46.67% | 14.97B | |
| +11.89% | 14.84B | |
| +57.74% | 14.38B |
- Stock Market
- Equities
- WBIO Stock
- Financials WPD Pharmaceuticals Inc.
